扶正抗瘤方联合化疗治疗晚期非小细胞肺癌患者的临床研究

Clinical Research of Fuzheng Kangliu Formula Combined with Chemotherapy Treating Advanced NSCLC

目的:探究扶正抗瘤方联合化疗治疗晚期非小细胞肺癌患者的临床疗效。方法:选取88例确诊为晚期非小细胞肺癌,且前期应用化疗治疗无效的患者,将其随机分为试验组(n=44)和对照组(n=44)。对照组的44名患者继续应用单纯静脉化疗治疗,试验期为2周期(3周为1周期);试验组的44名患者在继续进行静脉化疗的同时,配合扶正抗瘤方连续治疗2周期,分别统计两种方法对晚期非小细胞肺癌患者的进展时间(TTP)和改善生活质量(QOL)评分。结果:在试验截止时间内,两组患者中位TTP无显著性差异;试验组患者治疗前后QOL评分有显著性差异。结论:用扶正抗瘤方配合治疗晚期非小细胞肺癌与单纯静脉化疗治疗相比,前者的QOL明显得到了改善,各功能领域及总健康状况得分显著上升,各项指标均优于单纯放疗治疗组,化疗效果得到了明显的提升,具有一定的临床疗效。

Objective: To observe the clinical effects of Fuzheng Kangliu formula combined with chemotherapy treating advanced non-small cell lung cancer( NSCLC). Methods: 88 advanced NSCLC patients,for whom the intravenous chemotherapy were invalid,were randomly divided into the treatment group( n = 44) and the control group( n = 44). The patients in the control group received intravenous chemotherapy for 2 cycles of 6 weeks; whereas,the patients in the treatment group received Fuzheng Kangliu formula combined with intravenous chemotherapy treatment also for 2 cycles. The curative effects of the two groups were evaluated with scores of TTP( time to progression) and QOL( quality of life). Results: The median of TTP had no significant difference in the two groups after the treatment. After the treatment,the treatment group had significant difference in QOL scores,but the control group did not show obvious difference after the treatment. Conclusion: The therapy of Fuzheng Kangliu formula combined with chemotherapy has obvious effect on NSCLC,which improves general health status and QOL of the patients,compared to single intravenous chemotherapy.